Prostaglandin D 2 receptor antagonists in allergic disorders: safety, efficacy, and future perspectives
The DOI matches its Crossref record; 153 of the 153 references it cites were found in a registry or an index.
Abstract
Introduction: Prostaglandin D2 (PGD2) is a major cyclooxygenase mediator that is synthesized by activated human mast cells and other immune cells. The biological effects of PGD2 are mediated by D-prostanoid (DP1), DP2 (CRTH2) and thromboxane prostanoid (TP) receptors that are expressed on several immune and non-immune cells involved in allergic inflammation. PGD2 exerts various proinflammatory effects relevant to the pathophysiology of allergic disorders. Several selective, orally active, DP2 receptor antagonists and a small number of DP1 receptor antagonists are being developed for the treatment of allergic disorders.Areas covered: The role of DP2 and DP1 receptor antagonists in the treatment of asthma and allergic rhinitis.Expert opinion: Head-to-head studies that compare DP1 antagonists with the standard treatment for allergic rhinitis are necessary to verify the role of these novel drugs as mono- or combination therapies. Further clinical trials are necessary to verify whether DP2 antagonists as monotherapies or, more likely, as add-on therapies, will be effective for the treatment of different phenotypes of adult and childhood asthma. Long-term studies are necessary to evaluate the safety of targeted anti-PGD2 treatments.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Prostaglandin D2 and its receptor (PGDR2/CRTH2) play an important role in the generation of inflammation151.”
From Atopic dermatitis: an expanding therapeutic pipeline for a complex disease (2022) · cites this paper as [151]
Citations
Cites
Asthma phenotypes: the evolution from clinical to molecular approaches
Wenzel, S. E. (2012) · Nature Medicine · doi:10.1038/nm.2678 · Cited by 2,412
Mepolizumab Treatment in Patients with Severe Eosinophilic Asthma
Ortega, H. G., Liu, M. C., Pavord, I. D., Brusselle, G. G., FitzGerald, J. M., Chetta, A., Humbert, M., Katz, L. E., Keene, O. N., Yancey, S. W., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1403290 · Cited by 2,322 · cited 1×
“For example, blood eosinophilia or Th2 overexpression are used to select patients candidates for treatment with mAbs anti-IL-5/IL-5Rα [5,8,10,15] or anti-IL-4Rα [16,17].”
BackgroundPavord, I. D., Korn, S., Howarth, P., Bleecker, E. R., Buhl, R., Keene, O. N., Ortega, H., & Chanez, P. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60988-x · Cited by 2,221
Dupilumab Efficacy and Safety in Moderate-to-Severe Uncontrolled Asthma
Castro, M., Corren, J., Pavord, I. D., Maspero, J., Wenzel, S., Rabe, K. F., Busse, W. W., Ford, L., Sher, L., FitzGerald, J. M., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1804092 · Cited by 1,986 · cited 3×
“[16,17] have been shown effective in Th2 phenotypes of severe asthma.”
BackgroundLambrecht, B. N., & Hammad, H. (2015) · Nature Immunology · doi:10.1038/ni.3049 · Cited by 1,673 · cited 1×
“Bronchial asthma and allergic rhinitis are common chronic clinical conditions that affect more than 30% of adults in industrialized societies [1,2].”
BackgroundOral Glucocorticoid-Sparing Effect of Mepolizumab in Eosinophilic Asthma
Bel, E. H., Wenzel, S. E., Thompson, P. J., Prazma, C. M., Keene, O. N., Yancey, S. W., Ortega, H. G., & Pavord, I. D. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1403291 · Cited by 1,661 · cited 1×
“For example, blood eosinophilia or Th2 overexpression are used to select patients candidates for treatment with mAbs anti-IL-5/IL-5Rα [5,8,10,15] or anti-IL-4Rα [16,17].”
BackgroundType 2 inflammation in asthma — present in most, absent in many
Fahy, J. V. (2015) · Nature Reviews Immunology · doi:10.1038/nri3786 · Cited by 1,654 · cited 1×
“Asthma is a highly heterogeneous inflammatory disorder [80] that results from the interplay between multiple environmental”
BackgroundBleecker, E. R., FitzGerald, J. M., Chanez, P., Papi, A., Weinstein, S. F., Barker, P., Sproule, S., Gilmartin, G., Aurivillius, M., Werkström, V., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)31324-1 · Cited by 1,406
FitzGerald, J. M., Bleecker, E. R., Nair, P., Korn, S., Ohta, K., Lommatzsch, M., Ferguson, G. T., Busse, W. W., Barker, P., Sproule, S., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)31322-8 · Cited by 1,397 · cited 4×
“Monoclonal antibodies targeting IL-5 [5,7–12], IL-5Rα [13,14] or IL-4Rα (i.e., dupilumab) [16,17] have been shown effective in Th2 phenotypes of severe asthma.”
InfluentialLessons learned from the fate of AstraZeneca's drug pipeline: a five-dimensional framework
Cook, D., Brown, D., Alexander, R., March, R., Morgan, P., Satterthwaite, G., & Pangalos, M. N. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4309 · Cited by 1,344 · cited 1×
“patients with moderate-to-severe asthma stabilized on ICS and long-acting β2-adrenergic receptor agonists failed to meet the primary endpoint and it was discontinued [119].”
Background
Research works printed but not linked: 8
- Fuller RW, 1986, Am Rev Respir Dis, 133, 252
- Schulman ES, 1981, Am Rev Respir Dis, 124, 402
- Small P, 1994, Ann Allergy, 73, 252
- Singh D, 2017, Clin Pharmacol, 9, 165
- Fitzgerald MF, 2013, Am J Respir Crit Care Med, 187, A2617
- Fitzgerald M, 2013, ATS Conference Proceedings, Pennsylvania, A3874
- Bell S, 2012, Am J Respir Crit Care Med, 185, A2756
- Petsky HL, 2017, Cochrane Database Syst Rev, 8, CD005603
Cited by
Lactate modulation of immune responses in inflammatory versus tumour microenvironments
Certo, M., Tsai, C.-H., Pucino, V., Ho, P.-C., & Mauro, C. (2021) · Nature Reviews Immunology · doi:10.1038/s41577-020-0406-2 · Cited by 924
Self-citationAtopic dermatitis: an expanding therapeutic pipeline for a complex disease
Bieber, T. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00266-6 · Cited by 623
Biologics and airway remodeling in severe asthma
Varricchi, G., Ferri, S., Pepys, J., Poto, R., Spadaro, G., Nappi, E., Paoletti, G., Virchow, J. C., Heffler, E., & Canonica, W. G. (2022) · Allergy · doi:10.1111/all.15473 · Cited by 254
Self-citationEicosanoid signalling blockade protects middle-aged mice from severe COVID-19
Wong, L.-Y. R., Zheng, J., Wilhelmsen, K., Li, K., Ortiz, M. E., Schnicker, N. J., Thurman, A., Pezzulo, A. A., Szachowicz, P. J., Li, P., et al. (2022) · Nature · doi:10.1038/s41586-022-04630-3 · Cited by 178
The Intriguing Role of Interleukin 13 in the Pathophysiology of Asthma
Marone, G., Granata, F., Pucino, V., Pecoraro, A., Heffler, E., Loffredo, S., Scadding, G. W., & Varricchi, G. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.01387 · Cited by 171
Self-citation
Metadata
- Authors
- Marone, G., Galdiero, M. R., Pecoraro, A., Pucino, V., Criscuolo, G., Triassi, M., & Varricchi, G.
- Affiliations
- Ospedale Monaldi (IT)
- University of Naples Federico II (IT)
- Queen Mary University of London (GB)
- Corresponding author
- Varricchi, Gilda
- ORCID
- Venue
- Expert Opinion on Investigational Drugs
- Publisher
- Informa UK Limited
- Published
- 2018-12-07
- Volume
- 28
- Issue
- 1
- Pages
- 73-84
- ISSN
- 1354-3784 (ISSN-L)
- 1744-7658
- OpenAlex
- W2902819785
- Cited by
- 62
- References
- 153
- Citations by year
- 2026: 3 · 2025: 4 · 2024: 5 · 2023: 4 · 2022: 12 · 2021: 15 · 2020: 9 · 2019: 10
- FWCI
- 5.87
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Expert Opinion on Investigational Drugs (publishedVersion)
- PubMed (publishedVersion)
- CINECA IRIS Institutial research information system (University of Pisa) (submittedVersion)
- Funders
- Regione Campania CISI-Lab Project, CRèME Projec, and TIMING Project
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Asthma and respiratory diseases
- Health Sciences › Medicine › Pharmacology (medical) › Inflammatory mediators and NSAID effects
- Life Sciences › Immunology and Microbiology › Immunology › Mast cells and histamine
- Keywords
- prostaglandin D2, CRTH2, allergic rhinitis, asthma, allergic inflammation, mast cells, drug safety, drug efficacy
- MeSH terms
- Adult, Animals, Asthma, Child, Humans, Mast Cells, Receptors, Immunologic, Receptors, Prostaglandin, Drug Design, Prostaglandin D2, Anti-Allergic Agents, Rhinitis, Allergic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Prostaglandin D 2 receptor antagonists in allergic disorders: safety, efficacy, and future perspectives. https://app.cochat.ai/papers/10.1080/13543784.2019.1555237
- The paper
- Marone, G., Galdiero, M. R., Pecoraro, A., Pucino, V., Criscuolo, G., Triassi, M., & Varricchi, G. (2019). Prostaglandin D 2 receptor antagonists in allergic disorders: safety, efficacy, and future perspectives. Expert Opinion on Investigational Drugs. https://doi.org/10.1080/13543784.2019.1555237
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.